Synthego

Valuation $1B

About Synthego

Synthego is a genome engineering company that enables access to CRISPR to accelerate life science research and development.
Headquarters Synthego, Redwood City
Founded 2012-07-01
Industry Artificial Intelligence (AI), Biotechnology, Genetics, Industrial Automation, Innovation Management, Life Science, Machine Learning, Software
Last Funding Type Series E
Valuation 1
Total Funding $459.69 million dollars
IPO Status Private

Financial

Synthego may be growing as indicated by its strategic corporate decisions. The company has announced a CEO transition with a focus on enabling CRISPR therapeutics, which suggests a reorganization to better align with its growth strategy in the biotechnology sector. Additionally, Synthego has spun out a new entity, EditCo Bio, centered around its engineered cell platform, indicating an expansion of its business operations and potentially an increase in its market presence. These moves imply an active approach to scaling its offerings and refining its leadership to support its growth trajectory in the genome engineering industry.

Synthego is advancing genome engineering through CRISPR technology. They focus on guide RNA sequencing confirmation and design, as well as methods for analyzing nucleic acid sequences. Their research includes systems for modulating CRISPR activity and conjugated CRISPR-Cas complexes. Additionally, they develop methods for cryogenically arrayable stable transfection and systems for processing cells, including automated oligonucleotide synthesis. These efforts highlight Synthego's commitment to enhancing CRISPR-based gene editing and cell processing technologies.

Synthego's CEO will step down to focus the company on CRISPR therapeutics. Concurrently, Synthego spins off EditCo Bio, transferring its engineered cell solutions to the new entity. This strategic move aims to enhance focus on therapeutic applications of CRISPR technology.
Funding Rounds 9
Number of Lead Investors 5
Total Funding Amount  $459.69 million dollars
Number of Investors 29

Related Angels

Chih-Yuan Yang
View profile